Spots Global Cancer Trial Database for condylomata acuminata
Every month we try and update this database with for condylomata acuminata cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| An Investigational Study of Gardasil™ (qHPV Vaccine) in Reducing the Incidence of Anogenital Warts in Young Men (V501-020) | NCT00090285 | Condylomata Acu... | (Gardasil™) hum... Comparator: pla... | 16 Years - 26 Years | Merck Sharp & Dohme LLC | |
| Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017) | NCT03546842 | Papillomavirus ... Uterine Cervica... Vulvar Neoplasm... Vaginal Neoplas... Adenocarcinoma ... Condylomata Acu... | 9vHPV vaccine | 9 Years - 26 Years | Merck Sharp & Dohme LLC | |
| Broad Spectrum HPV Vaccine Tolerability, Immunogenicity, and Efficacy Study (V502-003) | NCT00365443 | Cervical Cancer Condylomata Acu... | V502 | 16 Years - 26 Years | Merck Sharp & Dohme LLC | |
| Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli) | NCT04537156 | Cervical Intrae... Cervical Cancer Condylomata Acu... | Nonavalent HPV ... Bivalent HPV va... | 18 Years - 45 Years | Xiamen University | |
| Peginterferon α-2b Combined CO2 Laser in Condylomata Acuminata | NCT06430190 | Condylomata Acu... | Peginterferon α... Peginterferon α... CO2 laser | 18 Years - 65 Years | First People's Hospital of Hangzhou | |
| Safety and Efficacy of Immune Therapy for Condyloma | NCT03158480 | Condylomata Acu... | DC-CIK immunoth... | 20 Years - 50 Years | Shenzhen Second People's Hospital | |
| Intralesional HPV Vaccine for Condylomata | NCT05087849 | Human Papilloma... Warts Warts, Genital Condyloma Condylomata Acu... | nonavalent huma... | 18 Years - | University of California, San Francisco | |
| Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts | NCT00674739 | Genital Warts | Imiquimod 3.75% imiquimod... placebo cream | 12 Years - | Graceway Pharmaceuticals, LLC | |
| Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) Versus Gardasil®9 in Healthy Females 18-26 Years of Age | NCT04782895 | Cervical Cancer Condylomata Acu... | Recombinant Hum... Gardasil®9 | 18 Years - 26 Years | Xiamen University | |
| A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts | NCT03981822 | Condylomata Acu... Papillomavirus ... Skin Diseases, ... Skin Diseases, ... Skin Diseases Sexually Transm... Sexually Transm... Warts | VP-102 and appl... Placebo | 18 Years - | Verrica Pharmaceuticals Inc. | |
| Efficacy and Safety Study of Polyphenon E to Treat External Genital Warts | NCT00449982 | Condylomata Acu... | Polyphenon E Oi... | 18 Years - | MediGene | |
| Broad Spectrum HPV Vaccine Tolerability, Immunogenicity, and Efficacy Study (V502-003) | NCT00365443 | Cervical Cancer Condylomata Acu... | V502 | 16 Years - 26 Years | Merck Sharp & Dohme LLC | |
| Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts | NCT00674739 | Genital Warts | Imiquimod 3.75% imiquimod... placebo cream | 12 Years - | Graceway Pharmaceuticals, LLC | |
| Broad Spectrum HPV Vaccine Tolerability, Immunogenicity, and Efficacy Study (V502-003) | NCT00365443 | Cervical Cancer Condylomata Acu... | V502 | 16 Years - 26 Years | Merck Sharp & Dohme LLC | |
| Evaluation of the Effectiveness of an Alcohol Based Hand Gel for the Reduction of Warts on the Hands | NCT00973856 | Papillomavirus ... Warts Condylomata Acu... Epidermodysplas... | PURELL VF481 Placebo Solutio... | 18 Years - 75 Years | Cleveland Clinic Akron General | |
| Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts | NCT00735462 | Genital Warts | 2.5% imiquimod ... 3.75% imiquimod... Placebo cream | 12 Years - | Graceway Pharmaceuticals, LLC | |
| Safety and Efficacy Study of Topical Ranpirnase to Treat Genital Warts (HPV) | NCT02535104 | Condylomata Acu... Papillomavirus ... Sexually Transm... | Ranpirnase Vehicle | 18 Years - 60 Years | Tamir Biotechnology, Inc. | |
| Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) Versus Gardasil®9 in Healthy Females 18-26 Years of Age | NCT04782895 | Cervical Cancer Condylomata Acu... | Recombinant Hum... Gardasil®9 | 18 Years - 26 Years | Xiamen University | |
| Peginterferon α-2b Combined CO2 Laser in Condylomata Acuminata | NCT06430190 | Condylomata Acu... | Peginterferon α... Peginterferon α... CO2 laser | 18 Years - 65 Years | First People's Hospital of Hangzhou | |
| Epidemiology, Costs and Psychosocial Consequences of Genital Warts in Valparaiso, Chile | NCT01483794 | Condylomata Acu... | 18 Years - 70 Years | Universidad de Valparaiso | ||
| Intralesional HPV Vaccine for Condylomata | NCT05087849 | Human Papilloma... Warts Warts, Genital Condyloma Condylomata Acu... | nonavalent huma... | 18 Years - | University of California, San Francisco | |
| Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017) | NCT03546842 | Papillomavirus ... Uterine Cervica... Vulvar Neoplasm... Vaginal Neoplas... Adenocarcinoma ... Condylomata Acu... | 9vHPV vaccine | 9 Years - 26 Years | Merck Sharp & Dohme LLC | |
| Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts | NCT00735462 | Genital Warts | 2.5% imiquimod ... 3.75% imiquimod... Placebo cream | 12 Years - | Graceway Pharmaceuticals, LLC | |
| Human Papillomavirus (HPV) Types Present in External Genital Warts (EGW) in the Argentinean Population | NCT01598779 | Condylomata Acu... | 15 Years - 45 Years | University of Buenos Aires | ||
| Efficacy and Safety Profiles of SR-T100 Gel on External Genital Warts/Condyloma Acuminate(EGWs) | NCT01796821 | Condyloma Acumi... Genital Warts Condylomata Acu... Venereal Warts | Vehicle gel SR-T100 gel wit... SR-T100 gel wit... | 20 Years - | G&E Herbal Biotechnology Co., LTD | |
| A Trial of the Efficacy and Safety of Topical Nitric Oxide in Patients With Anogenital Warts | NCT02015260 | Anogenital Wart... Condylomata Acu... | Topical NO Placebo | 18 Years - | University of Aberdeen | |
| A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts | NCT03981822 | Condylomata Acu... Papillomavirus ... Skin Diseases, ... Skin Diseases, ... Skin Diseases Sexually Transm... Sexually Transm... Warts | VP-102 and appl... Placebo | 18 Years - | Verrica Pharmaceuticals Inc. | |
| Human Papillomavirus (HPV) Types Present in External Genital Warts (EGW) in the Argentinean Population | NCT01598779 | Condylomata Acu... | 15 Years - 45 Years | University of Buenos Aires | ||
| A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of External Genital Warts | NCT03158974 | Condylomata Acu... | East Indian San... | 18 Years - 65 Years | ViroXis Corporation | |
| Efficacy of Intralesional MMR Vaccine,Intralesional Candidal Antigen&Topical Podophyllin in Treatment of Genital Warts | NCT03853785 | Condylomata Acu... | MMR vaccine Candida antigen Topical Podophy... | 3 Years - 50 Years | Assiut University | |
| A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts | NCT03981822 | Condylomata Acu... Papillomavirus ... Skin Diseases, ... Skin Diseases, ... Skin Diseases Sexually Transm... Sexually Transm... Warts | VP-102 and appl... Placebo | 18 Years - | Verrica Pharmaceuticals Inc. | |
| Safety and Efficacy Study of Topical Ranpirnase to Treat Genital Warts (HPV) | NCT02535104 | Condylomata Acu... Papillomavirus ... Sexually Transm... | Ranpirnase Vehicle | 18 Years - 60 Years | Tamir Biotechnology, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
